Geron reports Q4/FY2023 results; cash $378M, PDUFA June 16, 2024 for imetelstat

GERON CORP

2023-FY EPS reported -$0.32 revenue$237,000

Cash, cash equivalents and marketable securities of $378.1M as of Dec 31, 2023; cash runway into Q3 2025.
FDA PDUFA action date June 16, 2024 for imetelstat NDA in transfusion-dependent LR-MDS; ODAC meeting March 14, 2024.
Total operating expenses FY2023: $194.1M (R&D $125M, G&A $69.1M); FY2024 guidance $270-280M.
Phase 3 IMpactMF for myelofibrosis achieved 50% enrollment; interim analysis expected H1 2025.
Revenue minimal at $237,000 for FY2023; company plans to grow to ~270 employees by end of 2024 if approved.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GERON CORP reported the fourth quarter and full year 2023 results: revenue $23,000 and $237,000, respectively.

Period: the fourth quarter and full year 2023
Revenue: $23,000 and $237,000, respectively
Result: reported results

Exact text from the filing

loan facility, will be sufficient to fund its projected operating expenses into the third quarter of 2025. Revenues for the three and twelve months ended December 31, 2023, were $23,000 and $237,000, respectively, compared to $103,000 and $596,000 for the comparable 2022 periods. Revenues in both years primarily reflect estimated royalties from sales of

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

GERON CORP filing history →

Source: SEC EDGAR

accession 0000950170-24-021658

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.